Comprehensive evaluation of half dose ticagrelor in the treatment of ACS patients after PCI

Corresponding author: yaojiaqi, 1083518819@qq.com

DOI: 10.12201/bmr.202407.00070

•  

  Abstract: Objective Asian patients with acute coronary syndrome (ACS) are often susceptible to the influence of standard doses of ticagrelor, thereby increasing the risk of bleeding events. Therefore, it is crucial to retrospectively analyze whether half dose ticagrelor can provide better safety and similar therapeutic effects. Methods Collect clinical data of ACS patients who successfully underwent percutaneous coronary intervention (PCI) at the First Affiliated Hospital of Ningbo University from January 2017 to November 2019. According to the dosage of ticagrelor used, they were divided into a standard dose ticagrelor group (90mg, 56 cases) and a half dose ticagrelor group (45mg, 52 cases). Comparing the clinical outcomes of two medication regimens, a landmark analysis was conducted on clinical events during different follow-up periods, with the safety endpoint defined as bleeding related complications after PCI in patients. The efficacy endpoint is major adverse cardiovascular and cerebrovascular events (MACCE). Results During the entire follow-up period, according to the bleeding academic research consortium (BARC) standards, the cumulative incidence of type 1, 2, or 3 bleeding in the half dose ticagrelor group was lower than that in the standard dose group (P<0.05), especially after more than 1 year (P<0.05). There was no significant difference in the incidence of MACCE between different doses of ticagrelor (P>0.05). Conclusion Half dose ticagrelor can reduce the risk of type 1, 2, or 3 bleeding and its efficacy in MACCE is not inferior to standard dose treatment. Therefore, providing better evidence for the use of half dose ticagrelor between long-term bleeding and ischemia after PCI in ACS patients in the southern population.

  Key words: coronary heart disease ；ticagrelor ；bleeding complications；adverse event

  Submit time: 31 July 2024

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• ZHANG Yi-ying, DU Yu, LI Meng, LI Yuan-bai, YANG Shuo, Liu Fang-zhou, WANG Jing, LI Yi-hao, YANG Yang. Analysis of the characteristics of ancient prescriptions for coronary heart disease based on association rules. 2021. doi: 10.12201/bmr.202110.00027

  Zhangshaoqiang. Network Meta-analysis of Different Efficacy Combinations of Traditional Chinese Medicine Compounds Combined With Conventional Western Medicines in the Treatment of Coronary Heart Disease Combined with Depression. 2024. doi: 10.12201/bmr.202410.00055

  liruiyao, xujingyi, daihaoyu, sunhuiwen, wutianxing. Deep confidence network-based prediction of microvascular complications in type 2 diabetes mellitus. 2024. doi: 10.12201/bmr.202404.00021

  You Liping, WangShiyu. Extraction of Adverse Drug Events from Social Media Based on FrameNet Semantic Analysis YOU Liping, WANG Shiyu, LI Chaofan, College of Economics and Management, Shanxi University, Taiyuan 030006, China.. 2022. doi: 10.12201/bmr.202211.00006

  Chen Yuan, Chen Shiqi, Zhang Rongxiang, Zhu Chenyang. Meta-analysis of the effects of ERAS in the perioperative period in patients with heart valve disease. 2024. doi: 10.12201/bmr.202410.00008

  liuyawen, xuqide, hanyi, wuzuoyan, aaa, aaaa, aaaaa, aaaaa, aaaa, aaaa, aaaaa, aaaa, aaaa, aaaa. Evaluation of the efficacy of Linalotide combined with PEG in the bowel preparation for colonoscopy of patients with chronic constipation. 2024. doi: 10.12201/bmr.202411.00023

  A Study on the Prediction of Acute Coronary Syndrome Based on Coronary Fat Attenuation Index and Laboratory Indicators. 2024. doi: 10.12201/bmr.202409.00001

  XuHong. Advances in the treatment of osteopenia-seropathic obesity syndrome in the elderly. 2024. doi: 10.12201/bmr.202411.00064

  Wangzhong. Correlation of Serum soluble TREM2 with Acute coronary syndrome in the elderly. 2024. doi: 10.12201/bmr.202412.00086

  The predictive value ofperipheral blood inflammatory makers for lower extremity deep venous thrombosis after hip fracture surgery in patients. 2024. doi: 10.12201/bmr.202408.00016

• ID	Submit time	Number	Download
  1	2024-07-18	bmr.202407.00070V1	Download

• Public  Anonymous  To author only Submit Comments